Nls pharmaceutics ceo issues letter to shareholders

Zurich, switzerland / accesswire / december 11, 2024 / nls pharmaceutics ltd. (nasdaq:nlsp)(nasdaq:nlspw) ("nls" or the "company"), a swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that its chief executive officer, alex zwyer, has issued the following letter to shareholders: dear valued shareholders, as we move forward with exciting developments at nls, i want to update you on the significant progress we've made, key challenges we've overcome, and the strategic opportunities that lie ahead-especially as we approach the expected closing of our transformative merger with kadimastem ltd.
NLSP Ratings Summary
NLSP Quant Ranking